(Q34700544)

4 August 2017

1 reference

title

HIV drug development: the next 25 years (English)

1 reference

4 August 2017

Charles Flexner

1

1 reference

4 August 2017

1 December 2007

1 reference

Nature Reviews Drug Discovery

4 August 2017

1 reference

4 August 2017

6

1 reference

4 August 2017

12

1 reference

4 August 2017

959-966

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd2336

4 August 2017

0 references

cites work

A randomized trial of the activity and safety of Ro 24-7429 (Tat antagonist) versus nucleoside for human immunodeficiency virus infection. The AIDS Clinical Trials Group 213 Team

1 reference

Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection

21 January 2018

1 reference

Antiretroviral therapies for treatment-experienced patients: current status and research challenges

21 January 2018

1 reference

PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing

31 March 2020

1 reference

Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals

31 March 2020

1 reference

Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211

31 March 2020

1 reference

Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection.

31 March 2020

1 reference

Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects

31 March 2020

1 reference

Towing of sensory axons by their migrating target cells in vivo

31 March 2020

1 reference

The role of a mutant CCR5 allele in HIV-1 transmission and disease progression.

31 March 2020

1 reference

CCR5 deficiency increases risk of symptomatic West Nile virus infection

31 March 2020

1 reference

Declining CD4 T-cell counts in a person infected with nef-deleted HIV-1

31 March 2020

1 reference

Charting HIV's remarkable voyage through the cell: Basic science as a passport to future therapy

31 March 2020

1 reference

APOBEC-mediated editing of viral RNA.

31 March 2020

1 reference

The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.

31 March 2020

1 reference

Class of Antiretroviral Drugs and the Risk of Myocardial Infarction

31 March 2020

1 reference

Out of Africa: what can we learn from HIV-2 about protective immunity to HIV-1?

31 March 2020

1 reference

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy

31 March 2020

1 reference

Antiretroviral activity of pegylated interferon alfa-2a in patients co-infected with HIV/hepatitis C virus

31 March 2020

1 reference

Lethal mutagenesis of HIV with mutagenic nucleoside analogs

31 March 2020

1 reference

Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry

31 March 2020

1 reference

Drug development strategies for salvage therapy: conflicts and solutions

31 March 2020

1 reference

Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial

31 March 2020

1 reference

A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen

31 March 2020

1 reference

Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant

31 March 2020

1 reference

Genetic variations in HLA-B region and hypersensitivity reactions to abacavir

31 March 2020

1 reference

Big physics, small doses: the use of AMS and PET in human microdosing of development drugs

31 March 2020

1 reference

Changes Over Time in Risk of Initial Virological Failure of Combination Antiretroviral Therapy

31 March 2020

1 reference

Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression

31 March 2020

1 reference

Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy

31 March 2020

1 reference

Mathematical approaches in the study of viral kinetics and drug resistance in HIV-1 infection

31 March 2020

1 reference

The HBV drug entecavir - effects on HIV-1 replication and resistance

31 March 2020

1 reference

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

31 March 2020

1 reference

A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency sy

31 March 2020

1 reference

Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRD2336

1 reference

PubMed ID

17932493

Dimensions Publication ID

4 August 2017

0 references

1 reference

PubMed ID

17932493